Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443579 + azacitidine + venetoclax in newly diagnosed AML
NCT06508489Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of SAR443579 in acute myeloid leukemia (AML), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest and 3 more. Started Aug 2024; status: terminated.
02
Drugs
SAR443579
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06508489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508489.